Stein U, Walther W, Shoemaker R H
Laboratory of Drug Discovery Research and Development, Division of Cancer Treatment, National Cancer Institute, Frederick, Maryland 21702-1201, USA.
Br J Cancer. 1996 Nov;74(9):1384-91. doi: 10.1038/bjc.1996.553.
Reversal of multidrug resistance (MDR) may offer a means of increasing the effectiveness of tumour chemotherapy. A variety of recent evidence indicates that cytokines may be particularly useful in this endeavour. To investigate the molecular mechanism by which cytokines may sensitise multidrug-resistant colon carcinoma cells, HCT15 and HCT116, to treatment with MDR-related drugs, we evaluated the effects of the human cytokines tumour necrosis factor alpha (TNF alpha), interleukin 2 (IL-2) and interferon gamma (IFN gamma) on mdr1 gene expression at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) and at the protein level with monoclonal antibodies by immuno flow cytometry. P-glycoprotein function was examined after accumulation of the fluorescent drug, doxorubicin, by flow cytometry. Chemosensitivity to doxorubicin and vincristine was analysed using the XTT assay. All three cytokines were found to modulate the MDR characteristics on mdr1 expression levels, P-glycoprotein function and measured chemosensitivity to MDR-associated anti-cancer drugs. This cytokine-induced reversal of MDR was strongly time dependent, with maximal effects after 48 and 72 h of cytokine treatment. If similar modulation of MDR phenotype can be obtained in in vivo models, it may be possible to verify the time course for modulation by cytokine treatment and to design appropriate clinical trials of this strategy for MDR reversal.
多药耐药性(MDR)的逆转可能为提高肿瘤化疗效果提供一种方法。最近的各种证据表明,细胞因子在这一过程中可能特别有用。为了研究细胞因子使多药耐药结肠癌细胞HCT15和HCT116对MDR相关药物治疗敏感的分子机制,我们通过逆转录-聚合酶链反应(RT-PCR)在mRNA水平以及用单克隆抗体通过免疫流式细胞术在蛋白质水平评估了人细胞因子肿瘤坏死因子α(TNFα)、白细胞介素2(IL-2)和干扰素γ(IFNγ)对mdr1基因表达的影响。通过流式细胞术检测荧光药物阿霉素蓄积后P-糖蛋白的功能。使用XTT法分析对阿霉素和长春新碱的化学敏感性。发现所有三种细胞因子均能调节mdr1表达水平、P-糖蛋白功能以及对MDR相关抗癌药物的化学敏感性等MDR特征。这种细胞因子诱导的MDR逆转具有强烈的时间依赖性,在细胞因子处理48和72小时后效果最佳。如果在体内模型中能获得类似的MDR表型调节,就有可能验证细胞因子治疗调节的时间进程,并设计出针对这种MDR逆转策略的合适临床试验。